Quantitation of rare circulating tumor cells by folate receptor α ligand-targeted PCR in bladder transitional cell carcinoma and its potential diagnostic significance
详细信息 查看全文
- 作者：Fuming Qi (1) (2) (3)
Yuchen Liu (1) (2) (4)
Rongchang Zhao (4) (7)
Xiangjun Zou (1) (4)
Lei Zhang (4) (6)
Jiaqiang Li (2) (4)
Yongqiang Wang (4)
Feiyang Li (4)
Xiaowen Zou (4)
Ye Xia (2) (4)
Xuliang Wang (2) (4)
Li Xing (4) (6)
Cailing Li (2)
Jingxiao Lu (8)
Junlong Tang (8)
Fangjian Zhou (5)
Chunxiao Liu (6)
Yaoting Gui (2)
Zhiming Cai (1) (4)
Xiaojuan Sun (8) - 关键词：Bladder transitional cell carcinoma ; Tumor specific ligand ; PCR ; Circulating tumor cell ; Folate receptor α
- 刊名：Tumor Biology
- 出版年：2014
- 出版时间：July 2014
- 年：2014
- 卷：35
- 期：7
- 页码：7217-7223
- 全文大小：506 KB
- 参考文献：1. Seigel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11-0. CrossRef
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-0. CrossRef
3. Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet. 2009;374(9685):239-9. CrossRef
4. Rubben H, Lutzeyer W, Fischer N, Deutz F, Lagrange W, Giani G. Natural history and treatment of low and high risk superficial bladder tumors. J Urol. 1988;139(2):283-.
5. Wu XR. Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer. 2005;5(9):713-5. CrossRef
6. Shariat SF, Karakiewicz PI, Ashfaq R, Lerner SP, Palapattu GS, Cote RJ, et al. Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. Cancer. 2008;112(2):315-5. CrossRef
7. Vrooman OP, Witjes JA. Molecular markers for detection, surveillance and prognostication of bladder cancer. Int J Urol. 2009;16(3):234-3. CrossRef
8. Duggan BJ, Gray SB, McKnight JJ, Watson CJ, Johnston SR, Williamson KE. Oligoclonality in bladder cancer: the implication for molecular therapies. J Urol. 2004;171(1):419-5. CrossRef
9. Hafner C, Knuechel R, Zanardo L, Dietmaier W, Blaszyk H, Cheville J, et al. Evidence for oligoclonality and tumor spread by intraluminal seeding in multifocal urothelial carcinomas of the upper and lower urinary tract. Oncogene. 2001;20(35):4910-. CrossRef
10. Veltri RW, Makarov DV. Nucleic acid-based marker approaches to urologic cancers. Urol Oncol. 2006;24(6):510-7. CrossRef
11. Paterlini-Brechot P, Benali NL. Circulating tumor cells (CTC) detection: clinical impact and future directions. Cancer Lett. 2007;253(2):180-04. CrossRef
12. Paterlini-Brechot P, Benali NL. Prognostic value of circulating tumor cells in nonmuscle invasive bladder cancer: a cell search analysis. Ann Oncol. 2012;23(9):2352-. CrossRef
13. Mou L, Xu JY, Li W, Lei X, Wu Y, Xu G, et al. Identification of vimentin as a novel target of HSF4 in lens development and cataract by proteomic analysis. Invest Ophthalmol Vis Sci. 2010;51(1):396-04. CrossRef
14. Liu Y, Huang W, Zhou D, Han Y, Duan Y, Zhang X, et al. Synthesizing oncogenic signal-processing systems that function as both “signal counters-and “signal blockers-in cancer cells. Mol BioSyst. 2013;9(7):1909-8. CrossRef
15. Wu S, Wang Y, Sun L, Zhang Z, Jiang Z, Qin Z, et al. Decreased expression of dual-specificity phosphatase 9 is associated with poor prognosis in clear cell renal cell carcinoma. BMC Cancer. 2011;11:413-0. CrossRef
16. Lou J, Ben S, Yang G, Liang X, Wang X, Ni S, et al. Quantification of rare circulating tumor cells in non-small cell lung cancer by ligand-targeted PCR. PLoS One. 2013;8(12):e80458. CrossRef
17. Lotan Y, Elias K, Svatek RS, Bagrodia A, Nuss G, Moran B, et al. Bladder cancer screening in a high risk asymptomatic population using a point of care urine based protein tumor marker. J Urol. 2009;182(1):52-. CrossRef
18. Schmitz-Drager BJ, Tirsar LA, Schmitz-Drager C, D?rsam J, Mellan Z, Bismarck E, et al. Immunocytology in the assessment of patients with asymptomatic hematuria. World J Urol. 2008;26(1):31-. CrossRef
19. Lotan Y, Roehrborn CG. Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. Urology. 2003;61(1):109-8. CrossRef
20. Sturgeon CM, Duffy MJ, Stenman UH, Lamerz R, Fritsche HA, Gaarenstroom K, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers. Clin Chem. 2010;56(6):e11-8. CrossRef
21. Bassi P, De Marco V, De Lisa A, Mancini M, Pinto F, Bertoloni R, et al. Non-invasive diagnostic tests for bladder cancer: a review of the literature. Urol Int. 2005;75(3):193-00. CrossRef
22. Bastacky S, Ibrahim S, Wilczynski SP, Murphy WM. The accuracy of urinary cytology in daily practice. Cancer. 1999;87(3):118-8. CrossRef
23. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, B?hle A, Palou-Redorta J, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol. 2011;59(6):997-008. CrossRef
24. Stenzl A, Cowan NC, De Santis M, Jakse G, Kuczyk MA, Merseburger AS, et al. The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol. 2011;55(4):815-5. CrossRef
25. Patrick V, Bryant W, Steve G, Rosser CJ. Urine-based assays for the detection of bladder cancer. Biomark Med. 2009;3(3):265-4. CrossRef
26. Niedworok C, Rembrink V, Hakenberg OW, B?rgermann C, Rossi R, Schneider T, et al. The value of urinary cytology in the diagnosis of high grade urothelial tumors. Urologe A. 2009;48(9):1018. 1020-, 1024. CrossRef
27. Shariat SF, Casella R, Wians Jr FH, Ashfaq R, Balko J, Sulser T, et al. Risk stratification for bladder tumor recurrence, stage and grade by urinary nuclear matrix protein 22 and cytology. Eur Urol. 2004;45(3):304-3. CrossRef
28. van der Aa MN, Steyerberg EW, Sen EF, Zwarthoff EC, Kirkels WJ, van der Kwast TH, et al. Patients-perceived burden of cystoscopic and urinary surveillance of bladder cancer: a randomized comparison. BJU Int. 2008;101(9):1106-0. CrossRef
29. Kesari D, Kovisman V, Cytron S, Benjamin J. Effects on pain and anxiety of patients viewing their cystoscopy in addition to a detailed explanation: a controlled study. BJU Int. 2003;92(7):751-. CrossRef
30. Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoecon. 2003;21(18):1315-0. CrossRef
31. Pepe MS, Feng Z, Janes H, Bossuyt PM, Potter JD. Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards study design. J Natl Cancer Inst. 2008;100(20):1432-. CrossRef
32. S?reide K. Receiver-operating characteristic curve analysis in diagnostic, prognostic and predictive biomarker research. J Clin Pathol. 2009;62(1):1-. CrossRef - 作者单位：Fuming Qi (1) (2) (3)
Yuchen Liu (1) (2) (4)
Rongchang Zhao (4) (7)
Xiangjun Zou (1) (4)
Lei Zhang (4) (6)
Jiaqiang Li (2) (4)
Yongqiang Wang (4)
Feiyang Li (4)
Xiaowen Zou (4)
Ye Xia (2) (4)
Xuliang Wang (2) (4)
Li Xing (4) (6)
Cailing Li (2)
Jingxiao Lu (8)
Junlong Tang (8)
Fangjian Zhou (5)
Chunxiao Liu (6)
Yaoting Gui (2)
Zhiming Cai (1) (4)
Xiaojuan Sun (8)
1. Department of Urological Surgery, Shenzhen Second People’s Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, China
2. Guangdong and Shenzhen Key Laboratory of Male Reproductive Medicine and Genetics, Institute of Urology, Peking University Shenzhen Hospital, Shenzhen PKU-HKUST Medical Center, Shenzhen, China
3. Shantou University Medical College, Shantou, China
4. Shenzhen Key Laboratory of Genitourinary Tumor, Shenzhen Second People’s Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, 518035, China
7. Department of Research and Development, GenoSaber Biotech Co., Ltd., Shanghai, China
6. Department of Urology, Zhujiang Hospital of Southern Medical University, Guangzhou, China
8. Shenzhen Tumor Immuno-gene Therapy Clininical Application Engineering Lab, Biobank of Shenzhen Second People’s Hospital, The First Affiliated Hospital of Shenzhen University, 802 Room, Yinhua Building, 3002 West Sungang Road, Futian District, Shenzhen, 518035, China
5. Department of Urology, Sun Yat-Sen University Cancer Center, Guangzhou, China - ISSN：1423-0380
文摘
Numerous attempts for detection of circulating tumor cells (CTC) have been made to develop reliable assays for early diagnosis of cancers. In this study, we validated the application of folate receptor α (FRα) as the tumor marker to detect CTC through tumor-specific ligand PCR (LT-PCR) and assessed its utility for diagnosis of bladder transitional cell carcinoma (TCC). Immunohistochemistry for FRα was performed on ten bladder TCC tissues. Enzyme-linked immunosorbent assay (ELISA) for FRα was performed on both urine and serum specimens from bladder TCC patients (n--4 and n--0, respectively) and healthy volunteers (n--0 and n--3, respectively). Western blot analysis and qRT-PCR were performed to confirm the expression of FRα in bladder TCC cells. CTC values in 3-mL peripheral blood were measured in 57 bladder TCC patients, 48 healthy volunteers, and 15 subjects with benign urologic pathologies by the folate receptor α ligand-targeted PCR. We found that FRα protein was overexpressed in both bladder TCC cells and tissues. The levels of FRα mRNA were also much higher in bladder cancer cell lines 5637 and SW780 than those of leukocyte. Values of FRα were higher in both serum and urine specimens of bladder TCC patients than those of control. CTC values were also higher in 3-mL peripheral blood of bladder TCC patients than those of control (median 26.5?Cu/3?mL vs 14.0?Cu/3?mL). Area under the receiver operating characteristic (ROC) curve for bladder TCC detection was 0.819, 95?% CI (0.738-.883). At the cutoff value of 15.43?Cu/3?mL, the sensitivity and the specificity for detecting bladder cancer are 82.14 and 61.9?%, respectively. We concluded that quantitation of CTCs through FRα ligand-PCR could be a promising method for noninvasive diagnosis of bladder TCC.